The first PARP inhibitor to receive regulatory approval from the FDA was Olaparib in 2014, for the treatment of advanced‐stage BRCA1/2‐mutant ovarian cancers refractory to ≥ 3 prior lines of therapy [42, 204]. Here, PARP1 is linked to ovarian carcinoma.